Literature DB >> 29663884

Advances in Tumor Targeted Liposomes.

A Jain1.   

Abstract

Cancer remains a deadly disease for effective treatment. Although anomalous tumor microenvironment is now widely exploited for targeted chemotherapy, safe and efficacious drug delivery to tumor cells is not still warranted. Liposomes are promising biodegradable and biocompatible nanocarriers having potential amenability for surface and internal modifications, and extraordinary capability to carry both hydrophilic as well as hydrophobhic drugs. Meticulous fabrication of liposomes with tumor selective ligand(s) and PEGylation reduces immunogenicity and increase target-specificity. This review focuses on critical developmental aspects of liposomes to target cancer cells exploiting Enhanced Permeability and Retention (EPR) effect and tumor-selective ligands such as folate, transferrin, peptides etc. Moreover, stimuli-responsive smart liposomes (triggers: pH, temperature, enzymes, magnetic field, ultrasound, and redox potential etc.) are also investigated for enhancement of drug delivery to tumors. This review summarizes advances in tumor-targeted liposomes via various means of targeting. This knowledgeable assemblage of advances in liposomal approaches will render new insights to formulators and budding scientists to design cancer targeted liposomes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cancer; EPR effect; PEGylation; active targeting; anticancer agents; chemotherapy; ligand.

Mesh:

Substances:

Year:  2018        PMID: 29663884     DOI: 10.2174/1566524018666180416101522

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  9 in total

Review 1.  Oxidative stress in bladder cancer: an ally or an enemy?

Authors:  Fernando Mendes; Eurico Pereira; Diana Martins; Edgar Tavares-Silva; Ana Salomé Pires; Ana Margarida Abrantes; Arnaldo Figueiredo; Maria Filomena Botelho
Journal:  Mol Biol Rep       Date:  2021-03-17       Impact factor: 2.316

Review 2.  Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers.

Authors:  Manisit Das; Leaf Huang
Journal:  J Pharmacol Exp Ther       Date:  2018-12-12       Impact factor: 4.030

Review 3.  Delivery of cancer therapies by synthetic and bio-inspired nanovectors.

Authors:  Tina Briolay; Tacien Petithomme; Morgane Fouet; Nelly Nguyen-Pham; Christophe Blanquart; Nicolas Boisgerault
Journal:  Mol Cancer       Date:  2021-03-24       Impact factor: 27.401

Review 4.  Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma.

Authors:  Mahmood Barani; Mahwash Mukhtar; Abbas Rahdar; Saman Sargazi; Sadanand Pandey; Misook Kang
Journal:  Biosensors (Basel)       Date:  2021-02-20

Review 5.  Nanocarriers Call the Last Shot in the Treatment of Brain Cancers.

Authors:  Amin Mehrabian; Mohammad Mashreghi; Saba Dadpour; Ali Badiee; Leila Arabi; Seyedeh Hoda Alavizadeh; Seyedeh Alia Moosavian; Mahmoud Reza Jaafari
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system.

Authors:  Chutong Tian; Shunzhe Zheng; Xinying Liu; Ken-Ichiro Kamei
Journal:  J Nanobiotechnology       Date:  2022-07-20       Impact factor: 9.429

Review 7.  Dual-Targeting and Stimuli-Triggered Liposomal Drug Delivery in Cancer Treatment.

Authors:  Nour AlSawaftah; William G Pitt; Ghaleb A Husseini
Journal:  ACS Pharmacol Transl Sci       Date:  2021-06-01

8.  The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis.

Authors:  Ruijing Huang; Jian Li; Yibo Wang; Lihua Zhang; Xiaohui Ma; Hongyu Wang; Wenlei Li; Xiaodan Cao; Hanmei Xu; Jialiang Hu
Journal:  Int J Mol Sci       Date:  2018-09-10       Impact factor: 5.923

9.  Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC.

Authors:  Krishnendu Pal; Vijay Sagar Madamsetty; Shamit Kumar Dutta; Debabrata Mukhopadhyay
Journal:  Int J Nanomedicine       Date:  2019-07-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.